How to prevent and manage PARP inhibitor-related hematological toxicities in prostate cancer?
Abstract
Poly(ADP-ribose) polymerase inhibitors (PARPi) represent a significant advancement in the management of metastatic castration-resistant prostate cancer (mCRPC), substantially improving patient survival both as monotherapy and in combination with androgen receptor pathway inhibitors (ARPi). However, haematological toxicities, anaemia, thrombocytopenia and neutropenia, may compromise treatment continuity and thereby reduce effectiveness. Findings from phase III clinical trials and real-world studies have provided a more comprehensive understanding of these toxicities. Anaemia is the most common, occurring in 15 to 49% of patients at grade >= 3, typically within the first two months of treatment. This frequently results in treatment interruptions (15-26%) and dose reductions (11-46%). Investigations into the underlying pathophysiological mechanisms suggest that PARP-1 and PARP-2 proteins play a crucial role in haematopoiesis. Based on French expert recommendations, developed using a Delphi consensus methodology, practical algorithms have been established for the prevention and management of anaemia, neutropenia and thrombocytopenia. These include pre-therapy assessment, adjustments for patients with pre-existing haematological abnormalities, consideration of specific patient populations, guidance on the frequency and modalities of haematological monitoring, and management strategies for grade 2 and 3 toxicities. Effective multidisciplinary coordination among the oncologist, coordinating and/or advanced practice nurse, and pharmacist, alongside the use of digital tools that facilitate real-time monitoring and information sharing, are key strategies to enhance early detection of toxicities and maintain continuity of treatment.
Related
- Immunobiology and Immune-Related Toxicities of Cancer Immunotherapy: Organ-Specific Immune-Related Adverse Events, Cytokine Release Syndrome, and Immune Effector Cell–Associated Neurotoxicity Syndrome
- Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments
- Catalytically inactive PARP1 protein drives PARP inhibitor induced hematological toxicity
- A Multi-Kinase Inhibitor Screen Identifies mTOR Signaling as a Vulnerability in Advanced Prostate Cancer.
- TRPML1 inhibitor ML-SI1 suppresses prostate cancer through dual regulation of androgen receptor and polyamine metabolism
BibTeX
@article{cassuto2026prevent,
title = {{How to prevent and manage PARP inhibitor-related hematological toxicities in prostate cancer?}},
author = {Ophelie Cassuto and Antonin Schmitt and Carole Helissey and Aurélien Gobert and Romain Mathieu and Clara Bouteleux and Loïc Mourey and Nicolas Jovenin and Florence Joly},
journal = {Bulletin du Cancer},
year = {2026},
month = oct,
doi = {10.1016/j.bulcan.2026.04.009},
url = {https://hal.science/hal-05768627v1},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - How to prevent and manage PARP inhibitor-related hematological toxicities in prostate cancer?
AU - Ophelie Cassuto
AU - Antonin Schmitt
AU - Carole Helissey
AU - Aurélien Gobert
AU - Romain Mathieu
AU - Clara Bouteleux
AU - Loïc Mourey
AU - Nicolas Jovenin
AU - Florence Joly
PY - 2026
DA - 2026/10/23
JO - Bulletin du Cancer
DO - 10.1016/j.bulcan.2026.04.009
UR - https://hal.science/hal-05768627v1
AB - Poly(ADP-ribose) polymerase inhibitors (PARPi) represent a significant advancement in the management of metastatic castration-resistant prostate cancer (mCRPC), substantially improving patient survival both as monotherapy and in combination with androgen receptor pathway inhibitors (ARPi). However, haematological toxicities, anaemia, thrombocytopenia and neutropenia, may compromise treatment continuity and thereby reduce effectiveness. Findings from phase III clinical trials and real-world studies have provided a more comprehensive understanding of these toxicities. Anaemia is the most common, occurring in 15 to 49% of patients at grade >= 3, typically within the first two months of treatment. This frequently results in treatment interruptions (15-26%) and dose reductions (11-46%). Investigations into the underlying pathophysiological mechanisms suggest that PARP-1 and PARP-2 proteins play a crucial role in haematopoiesis. Based on French expert recommendations, developed using a Delphi consensus methodology, practical algorithms have been established for the prevention and management of anaemia, neutropenia and thrombocytopenia. These include pre-therapy assessment, adjustments for patients with pre-existing haematological abnormalities, consideration of specific patient populations, guidance on the frequency and modalities of haematological monitoring, and management strategies for grade 2 and 3 toxicities. Effective multidisciplinary coordination among the oncologist, coordinating and/or advanced practice nurse, and pharmacist, alongside the use of digital tools that facilitate real-time monitoring and information sharing, are key strategies to enhance early detection of toxicities and maintain continuity of treatment.
SN - 0007-4551
SN - 1769-6917
ER -